DNAPrint Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . DNAPrint Genomics
DNAG Stock  USD 0.00001  0.00  0.00%   
DNAPrint Genomics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing DNAPrint Genomics' valuation are provided below:
Gross Profit
446.4 K
Profit Margin
(2.36)
Market Capitalization
386.8 K
Enterprise Value Revenue
2.9228
Revenue
1.9 M
There are over one hundred nineteen available fundamental measures for DNAPrint Genomics, which can be analyzed over time and compared to other ratios. Active traders should verify all of DNAPrint Genomics latest fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself in the future. The DNAPrint Genomics' current Enterprise Value is estimated to increase to about 14.8 M, while Market Cap is projected to decrease to roughly 3.6 M.

DNAPrint Genomics Total Revenue

2.94 Million

Check DNAPrint Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DNAPrint Genomics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.8 M or Total Revenue of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or Days Sales Outstanding of 12.22. DNAPrint financial statements analysis is a perfect complement when working with DNAPrint Genomics Valuation or Volatility modules.
  
Build AI portfolio with DNAPrint Stock
Check out the analysis of DNAPrint Genomics Correlation against competitors.
For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.

DNAPrint Genomics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12.4 M11.8 M9.9 M
Slightly volatile
Other Current Liabilities2.2 M2.9 M2.4 M
Slightly volatile
Total Current Liabilities16.6 M15.8 M13.3 M
Slightly volatile
Accounts Payable3.6 M3.5 M2.9 M
Slightly volatile
Cash584.1 K683.9 K565.3 K
Slightly volatile
Total Liabilities16.9 M16.1 M13.5 M
Slightly volatile
Common Stock5.4 M5.3 M4.6 M
Slightly volatile
Property Plant Equipment770.3 K1.4 M1.2 M
Pretty Stable
Other Assets27.9 K26.6 K22.5 K
Slightly volatile
Long Term Debt144.1 K157.7 K167.9 K
Pretty Stable
Other Current Assets106.6 K70 K61.9 K
Slightly volatile
Other Liabilities45.1 K47.5 K67 K
Slightly volatile
Net Receivables63.8 K67.1 K94.5 K
Slightly volatile
Other Stockholder Equity7 M6.7 M5.6 M
Slightly volatile
Short and Long Term Debt205.2 K216 K271.4 K
Slightly volatile
Total Current Assets10.6 M10.1 M8.5 M
Slightly volatile
Short Term Debt205.2 K216 K271.4 K
Slightly volatile
Inventory168.8 K110.9 K99.7 K
Slightly volatile
Good Will260.8 K293.4 K320.2 K
Slightly volatile
Long Term Investments1.8 M2 M2.2 M
Slightly volatile
Intangible Assets220.4 K202.6 K229.4 K
Slightly volatile
Short Term Investments6.3 M7.1 M7.8 M
Slightly volatile

DNAPrint Genomics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative2.8 M3.7 M3 M
Slightly volatile
Total Revenue2.9 M2.8 M2.3 M
Slightly volatile
Gross Profit910.5 K867.2 K727.3 K
Slightly volatile
Research Development7.8 M7.4 M6.2 M
Slightly volatile
Cost Of Revenue983.6 K1.5 M1.5 M
Pretty Stable
Total Operating Expenses7.8 M13 M10.9 M
Pretty Stable

DNAPrint Genomics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures369.9 K352.3 K400.1 K
Slightly volatile
Change To Account Receivables32.9 K31.4 K26.6 K
Slightly volatile
Total Cash From Financing Activities3.3 M5.1 M4.2 M
Slightly volatile
Change To Liabilities2.5 M2.3 M2 M
Slightly volatile
Change To Netincome3.2 M4 M3.3 M
Slightly volatile
Sale Purchase Of Stock3.5 M3.5 M2.9 M
Slightly volatile
Net Borrowings1.1 M1.6 M1.3 M
Slightly volatile
Depreciation651.5 K620.5 K526.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.491.5783.2253
Slightly volatile
Days Sales Outstanding12.2212.8711.8072
Slightly volatile
Average Payables470.3 K677.4 K712.3 K
Very volatile
Capex To Depreciation0.350.330.3687
Slightly volatile
EV To Sales4.54.7386.5407
Slightly volatile
Inventory Turnover16.4515.6716.6852
Slightly volatile
Days Of Inventory On Hand22.924.1122.7894
Slightly volatile
Payables Turnover0.50.55770.52
Slightly volatile
Average Inventory92.1 K177.8 K180.5 K
Very volatile
Research And Ddevelopement To Revenue2.893.0410.1832
Slightly volatile
Capex To Revenue0.180.190.7492
Slightly volatile
Cash Per Share0.01110.02090.0212
Pretty Stable
Days Payables Outstanding7157531.3 K
Slightly volatile
Income Quality0.580.540.487
Very volatile
Intangibles To Total Assets0.04050.02520.025
Very volatile
Current Ratio0.340.570.5983
Very volatile
Receivables Turnover30.8329.3631.5384
Pretty Stable
Capex Per Share0.00230.00120.0015
Slightly volatile
Average Receivables130.9 K79.4 K85.3 K
Slightly volatile
Revenue Per Share0.01060.0060.0065
Slightly volatile
Interest Debt Per Share0.02410.02290.0198
Slightly volatile
Debt To Assets0.760.820.6903
Slightly volatile
Operating Cycle35.1336.9731.8373
Slightly volatile
Price Earnings To Growth Ratio0.00440.00460.0124
Slightly volatile
Days Of Payables Outstanding7157531.3 K
Slightly volatile
Total Debt To Capitalization1.931.831.9179
Slightly volatile
Return On Capital Employed2.132.282.5994
Slightly volatile
Quick Ratio0.330.570.5919
Very volatile
Cash Ratio0.03690.03890.0472
Slightly volatile
Days Of Inventory Outstanding22.924.1122.7894
Slightly volatile
Days Of Sales Outstanding12.2212.8711.8072
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.231.083
Slightly volatile
Fixed Asset Turnover1.081.771.7869
Pretty Stable
Debt Ratio0.760.820.6903
Slightly volatile
Price Sales Ratio1.491.5783.2253
Slightly volatile
Asset Turnover0.250.210.2231
Slightly volatile
Gross Profit Margin0.460.360.3381
Pretty Stable

DNAPrint Genomics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.6 M3.8 M5.2 M
Slightly volatile
Enterprise Value14.8 M11.5 M11.9 M
Slightly volatile

About DNAPrint Genomics Financial Statements

DNAPrint Genomics stakeholders use historical fundamental indicators, such as DNAPrint Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although DNAPrint Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DNAPrint Genomics' assets and liabilities are reflected in the revenues and expenses on DNAPrint Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DNAPrint Genomics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue2.8 M2.9 M
Cost Of Revenue1.5 M983.6 K
Research And Ddevelopement To Revenue 3.04  2.89 
Capex To Revenue 0.19  0.18 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(4.19)(3.98)

Currently Active Assets on Macroaxis

VVisa Class A
CCitigroup
SSentinelOne
MSFTMicrosoft
DDDupont De Nemours
When determining whether DNAPrint Genomics is a strong investment it is important to analyze DNAPrint Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DNAPrint Genomics' future performance. For an informed investment choice regarding DNAPrint Stock, refer to the following important reports:
How To Invest In DNAPrint
Details
Is DNAPrint Stock a good investment?
Details
What is DNAPrint Genomics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of DNAPrint Genomics Correlation against competitors.
For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Revenue Per Share
0.004
Quarterly Revenue Growth
(0.65)
Return On Assets
(1.05)
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY